The experimental, lab-made antibody leronlimab can completely prevent nonhuman primates from being infected with the monkey form of HIV, new research shows. The results will inform a future human clinical trial evaluating leronlimab as a potential pre-exposure prophylaxis, or PrEP, therapy to prevent human infection from the virus that causes AIDS.